Name: Analisi della citometria di massa delle risposte immunitarie sistemiche e locali nel carcinoma epatocellulare (Video) | JoVE Journal
Uploaded: 2025-04-25T13:00:00.000+00:00
Duration: 8 min 25 s
Description: Scopri la citometria di massa per analizzare le risposte immunitarie sistemiche e locali nel carcinoma epatocellulare. Questo metodo identifica 14 tipi cellulari distinti e supporta strategie terapeutiche personalizzate.

ai_agent_IP

ai_agent

maintenance

instantTrialDurationMinutes

isBiopharma

enableNewMyJoveSectionDesign

educationFeatures

seoMetaApi

ai_copilot_institution_blacklist

ai_chat_institution_blacklist

freeAccessWindow

ssoRoleCapture

scheduledMaintenanceBanner

joveLabsFeatures

disable_autoplay_for_bots

extended_trial_duration

5 minutes

<ol><li>Zhang, C. H., Cheng, Y., Zhang, S., Fan, J., Gao, Q. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Changing+epidemiology+of+hepatocellular+carcinoma+in+Asia%5BTitle%5D)+AND+%22Liver+Int%22%5BJournal%5D)">Changing epidemiology of hepatocellular carcinoma in Asia.</a> Liver Int. 42 (9), 2029-2041 (2022).</li>
<li>Renne, S. L., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Hepatocellular+carcinoma%3A+A+clinical+and+pathological+overview%5BTitle%5D)+AND+%22Pathologica%22%5BJournal%5D)">Hepatocellular carcinoma: A clinical and pathological overview.</a> Pathologica. 113 (3), 203-217 (2021).</li>
<li>Sayiner, M., Golabi, P., Younossi, Z. M. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Disease+burden+of+hepatocellular+carcinoma%3A+A+global+perspective%5BTitle%5D)+AND+%22Dig+Dis+Sci%22%5BJournal%5D)">Disease burden of hepatocellular carcinoma: A global perspective.</a> Dig Dis Sci. 64 (4), 910-917 (2019).</li>
<li>Zhang, X., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Risk+factors+and+prevention+of+viral+hepatitis-related+hepatocellular+carcinoma%5BTitle%5D)+AND+%22Front+Oncol%22%5BJournal%5D)">Risk factors and prevention of viral hepatitis-related hepatocellular carcinoma.</a> Front Oncol. 11, 686962(2021).</li>
<li>Zou, H., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Economic+burden+and+quality+of+life+of+hepatocellular+carcinoma+in+greater+China%3A+A+systematic+review%5BTitle%5D)+AND+%22Front+Public+Health%22%5BJournal%5D)">Economic burden and quality of life of hepatocellular carcinoma in greater China: A systematic review.</a> Front Public Health. 10, 801981(2022).</li>
<li>Li, Y., You, Z., Tang, R., Ma, X. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Tissue-resident+memory+t+cells+in+chronic+liver+diseases%3A+Phenotype%2C+development+and+function%5BTitle%5D)+AND+%22Front+Immunol%22%5BJournal%5D)">Tissue-resident memory t cells in chronic liver diseases: Phenotype, development and function.</a> Front Immunol. 13, 967055(2022).</li>
<li>Shen, K. Y., Zhu, Y., Xie, S. Z., Qin, L. X. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Immunosuppressive+tumor+microenvironment+and+immunotherapy+of+hepatocellular+carcinoma%3A+Current+status+and+prospectives%5BTitle%5D)+AND+%22J+Hematol+Oncol%22%5BJournal%5D)">Immunosuppressive tumor microenvironment and immunotherapy of hepatocellular carcinoma: Current status and prospectives.</a> J Hematol Oncol. 17 (1), 25(2024).</li>
<li>Oura, K., Morishita, A., Tani, J., Masaki, T. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Tumor+immune+microenvironment+and+immunosuppressive+therapy+in+hepatocellular+carcinoma%3A+A+review%5BTitle%5D)+AND+%22Int+J+Mol+Sci%22%5BJournal%5D)">Tumor immune microenvironment and immunosuppressive therapy in hepatocellular carcinoma: A review.</a> Int J Mol Sci. 22 (11), 5801(2021).</li>
<li>Chen, Y., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Effect+of+infiltrating+immune+cells+in+tumor+microenvironment+on+metastasis+of+hepatocellular+carcinoma%5BTitle%5D)+AND+%22Cell+Oncol%22%5BJournal%5D)">Effect of infiltrating immune cells in tumor microenvironment on metastasis of hepatocellular carcinoma.</a> Cell Oncol. 46 (6), 1595-1604 (2023).</li>
<li>Du, Q., An, Q., Zhang, J., Liu, C., Hu, Q. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Unravelling+immune+microenvironment+features+underlying+tumor+progression+in+the+single-cell+era%5BTitle%5D)+AND+%22Cancer+Cell+Int%22%5BJournal%5D)">Unravelling immune microenvironment features underlying tumor progression in the single-cell era.</a> Cancer Cell Int. 24 (1), 143(2024).</li>
<li>Xu, L., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Reshaping+the+systemic+tumor+immune+environment+%28stie%29+and+tumor+immune+microenvironment+%28time%29+to+enhance+immunotherapy+efficacy+in+solid+tumors%5BTitle%5D)+AND+%22J+Hematol+Oncol%22%5BJournal%5D)">Reshaping the systemic tumor immune environment (stie) and tumor immune microenvironment (time) to enhance immunotherapy efficacy in solid tumors.</a> J Hematol Oncol. 15 (1), 87(2022).</li>
<li>Mao, X., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Crosstalk+between+cancer-associated+fibroblasts+and+immune+cells+in+the+tumor+microenvironment%3A+New+findings+and+future+perspectives%5BTitle%5D)+AND+%22Mol+Cancer%22%5BJournal%5D)">Crosstalk between cancer-associated fibroblasts and immune cells in the tumor microenvironment: New findings and future perspectives.</a> Mol Cancer. 20 (1), 131(2021).</li>
<li>Roederer, M. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Spectral+compensation+for+flow+cytometry%3A+Visualization+artifacts%2C+limitations%2C+and+caveats%5BTitle%5D)+AND+%22Cytometry%22%5BJournal%5D)">Spectral compensation for flow cytometry: Visualization artifacts, limitations, and caveats.</a> Cytometry. 45 (3), 194-205 (2001).</li>
<li>Sahaf, B., Rahman, A., Maecker, H. T., Bendall, S. C. <a target="_blank" href="http://scholar.google.com/scholar?hl=en&safe=off&q=author%3aSahaf%2C+B+%22Biomarkers+for+immunotherapy+of+cancer%3A+Methods+and+protocols%22">Biomarkers for immunotherapy of cancer: Methods and protocols</a>. , Springer. New York, New York, NY. (2020).</li>
<li>Turaç, G., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Combined+flow+cytometric+analysis+of+surface+and+intracellular+antigens+reveals+surface+molecule+markers+of+human+neuropoiesis%5BTitle%5D)+AND+%22PLoS+One%22%5BJournal%5D)">Combined flow cytometric analysis of surface and intracellular antigens reveals surface molecule markers of human neuropoiesis.</a> PLoS One. 8 (6), e68519(2013).</li>
<li>Wu, K., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Redefining+tumor-associated+macrophage+subpopulations+and+functions+in+the+tumor+microenvironment%5BTitle%5D)+AND+%22Front+Immunol%22%5BJournal%5D)">Redefining tumor-associated macrophage subpopulations and functions in the tumor microenvironment.</a> Front Immunol. 11, 1731(2020).</li>
<li>Elaldi, R., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((High+dimensional+imaging+mass+cytometry+panel+to+visualize+the+tumor+immune+microenvironment+contexture%5BTitle%5D)+AND+%22Front+Immunol%22%5BJournal%5D)">High dimensional imaging mass cytometry panel to visualize the tumor immune microenvironment contexture.</a> Front Immunol. 12, 666233(2021).</li>
<li>Gadalla, R., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Validation+of+cytof+against+flow+cytometry+for+immunological+studies+and+monitoring+of+human+cancer+clinical+trials%5BTitle%5D)+AND+%22Front+Oncol%22%5BJournal%5D)">Validation of cytof against flow cytometry for immunological studies and monitoring of human cancer clinical trials.</a> Front Oncol. 9, 415(2019).</li>
<li>Ijsselsteijn, M. E., Van Der Breggen, R., Farina Sarasqueta, A., Koning, F., De Miranda, N. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((A+40-marker+panel+for+high+dimensional+characterization+of+cancer+immune+microenvironments+by+imaging+mass+cytometry%5BTitle%5D)+AND+%22Front+Immunol%22%5BJournal%5D)">A 40-marker panel for high dimensional characterization of cancer immune microenvironments by imaging mass cytometry.</a> Front Immunol. 10, 2534(2019).</li>
<li>Zhang, Q., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Mass+cytometry-based+peripheral+blood+analysis+as+a+novel+tool+for+early+detection+of+solid+tumours%3A+A+multicentre+study%5BTitle%5D)+AND+%22Gut%22%5BJournal%5D)">Mass cytometry-based peripheral blood analysis as a novel tool for early detection of solid tumours: A multicentre study.</a> Gut. 72 (5), 996-1006 (2023).</li>
<li>Zheng, B., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Trajectory+and+functional+analysis+of+pd-1%28high%29+cd4%28%2B%29cd8%28%2B%29+t+cells+in+hepatocellular+carcinoma+by+single-cell+cytometry+and+transcriptome+sequencing%5BTitle%5D)+AND+%22Adv+Sci%22%5BJournal%5D)">Trajectory and functional analysis of pd-1(high) cd4(+)cd8(+) t cells in hepatocellular carcinoma by single-cell cytometry and transcriptome sequencing.</a> Adv Sci. 7 (13), 2000224(2020).</li>
<li>Song, J., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Protocol+for+isolating+single+cells+from+human+pancreatic+cancer+tissues+and+analyzing+major+immune+cell+populations+using+flow+cytometry%5BTitle%5D)+AND+%22STAR+Protoc%22%5BJournal%5D)">Protocol for isolating single cells from human pancreatic cancer tissues and analyzing major immune cell populations using flow cytometry.</a> STAR Protoc. 4 (4), 102679(2023).</li>
<li>Simoni, Y., Chng, M. H. Y., Li, S., Fehlings, M., Newell, E. W. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Mass+cytometry%3A+A+powerful+tool+for+dissecting+the+immune+landscape%5BTitle%5D)+AND+%22Curr+Opin+Immunol%22%5BJournal%5D)">Mass cytometry: A powerful tool for dissecting the immune landscape.</a> Curr Opin Immunol. 51, 187-196 (2018).</li>
<li>Comi, M., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Coexpression+of+cd163+and+cd141+identifies+human+circulating+il-10-producing+dendritic+cells+%28dc-10%29%5BTitle%5D)+AND+%22Cell+Mol+Immunol%22%5BJournal%5D)">Coexpression of cd163 and cd141 identifies human circulating il-10-producing dendritic cells (dc-10).</a> Cell Mol Immunol. 17 (1), 95-107 (2020).</li>
<li>Fan, L., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((High-dimensional+single-cell+analysis+delineates+peripheral+immune+signature+of+coronary+atherosclerosis+in+human+blood%5BTitle%5D)+AND+%22Theranostics%22%5BJournal%5D)">High-dimensional single-cell analysis delineates peripheral immune signature of coronary atherosclerosis in human blood.</a> Theranostics. 12 (15), 6809-6825 (2022).</li>
<li>Sheng, J., et al. Human endogenous retrovirus activation contributes to biliary atresia pathogenesis through re-education of resident macrophages. <a target="_blank" href="http://scholar.google.com/scholar?hl=en&safe=off&q=author%3aSheng%2C+J+%22Biorxiv%22">Biorxiv</a>. , (2022).</li>
<li>Terekhova, M., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Single-cell+atlas+of+healthy+human+blood+unveils+age-related+loss+of+nkg2c%28%2B%29gzmb%28-%29cd8%28%2B%29+memory+t+cells+and+accumulation+of+type+2+memory+t+cells%5BTitle%5D)+AND+%22Immunity%22%5BJournal%5D)">Single-cell atlas of healthy human blood unveils age-related loss of nkg2c(+)gzmb(-)cd8(+) memory t cells and accumulation of type 2 memory t cells.</a> Immunity. 56 (12), 2836-2854.e9 (2023).</li>
<li>Sathaliyawala, T., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Distribution+and+compartmentalization+of+human+circulating+and+tissue-resident+memory+t+cell+subsets%5BTitle%5D)+AND+%22Immunity%22%5BJournal%5D)">Distribution and compartmentalization of human circulating and tissue-resident memory t cell subsets.</a> Immunity. 38 (1), 187-197 (2013).</li>
<li>Lee, S., Vu, H. M., Lee, J. H., Lim, H., Kim, M. S. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Advances+in+mass+spectrometry-based+single+cell+analysis%5BTitle%5D)+AND+%22Biology%22%5BJournal%5D)">Advances in mass spectrometry-based single cell analysis.</a> Biology. 12 (3), 395(2023).</li>
<li>Iyer, A., Hamers, A. A. J., Pillai, A. B. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Cytof+for+the+masses%5BTitle%5D)+AND+%22Front+Immunol%22%5BJournal%5D)">Cytof for the masses.</a> Front Immunol. 13, 815828(2022).</li>
<li>Yuan, X., Wang, J., Huang, Y., Shangguan, D., Zhang, P. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Single-cell+profiling+to+explore+immunological+heterogeneity+of+tumor+microenvironment+in+breast+cancer%5BTitle%5D)+AND+%22Front+Immunol%22%5BJournal%5D)">Single-cell profiling to explore immunological heterogeneity of tumor microenvironment in breast cancer.</a> Front Immunol. 12, 643692(2021).</li>
<li>Serban, G. M., Mănescu, I. B., Manu, D. R., Dobreanu, M. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Optimization+of+a+density+gradient+centrifugation+protocol+for+isolation+of+peripheral+blood+mononuclear+cells%5BTitle%5D)+AND+%22Acta+Marisiensis+-+Seria+Medica%22%5BJournal%5D)">Optimization of a density gradient centrifugation protocol for isolation of peripheral blood mononuclear cells.</a> Acta Marisiensis - Seria Medica. 64 (2), 83-90 (2018).</li>
<li>Shcherbakova, A., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Factors+affecting+cell+viability+during+the+enzymatic+dissociation+of+human+endocrine+tumor+tissues%5BTitle%5D)+AND+%22Biology+%28Basel%29%22%5BJournal%5D)">Factors affecting cell viability during the enzymatic dissociation of human endocrine tumor tissues.</a> Biology (Basel). 13 (9), 665(2024).</li>
<li>Devine, R. D., Alkhalaileh, H. S., Lyberger, J. M., Behbehani, G. K. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Alternative+methods+of+viability+determination+in+single+cell+mass+cytometry%5BTitle%5D)+AND+%22Cytometry+A%22%5BJournal%5D)">Alternative methods of viability determination in single cell mass cytometry.</a> Cytometry A. 99 (10), 1042-1053 (2021).</li>
<li>Gonzalez, V. D., Huang, Y. W., Fantl, W. J. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Mass+cytometry+for+the+characterization+of+individual+cell+types+in+ovarian+solid+tumors%5BTitle%5D)+AND+%22Methods+Mol+Biol%22%5BJournal%5D)">Mass cytometry for the characterization of individual cell types in ovarian solid tumors.</a> Methods Mol Biol. 2424, 59-94 (2022).</li>
<li>Zabransky, D. J., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Profiling+of+syngeneic+mouse+hcc+tumor+models+as+a+framework+to+understand+anti-pd-1+sensitive+tumor+microenvironments%5BTitle%5D)+AND+%22Hepatology%22%5BJournal%5D)">Profiling of syngeneic mouse hcc tumor models as a framework to understand anti-pd-1 sensitive tumor microenvironments.</a> Hepatology. 77 (5), 1566-1579 (2023).</li>
<li>Levine, L. S., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Single-cell+analysis+by+mass+cytometry+reveals+metabolic+states+of+early-activated+cd8%28%2B%29+t+cells+during+the+primary+immune+response%5BTitle%5D)+AND+%22Immunity%22%5BJournal%5D)">Single-cell analysis by mass cytometry reveals metabolic states of early-activated cd8(+) t cells during the primary immune response.</a> Immunity. 54 (4), 829-844.e5 (2021).</li>
<li>Lv, B., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Immunotherapy%3A+Reshape+the+tumor+immune+microenvironment%5BTitle%5D)+AND+%22Front+Immunol%22%5BJournal%5D)">Immunotherapy: Reshape the tumor immune microenvironment.</a> Front Immunol. 13, 844142(2022).</li>
<li>Zhou, Z., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Deciphering+the+tumor+immune+microenvironment+from+a+multidimensional+omics+perspective%3A+Insight+into+next-generation+car-t+cell+immunotherapy+and+beyond%5BTitle%5D)+AND+%22Mol+Cancer%22%5BJournal%5D)">Deciphering the tumor immune microenvironment from a multidimensional omics perspective: Insight into next-generation car-t cell immunotherapy and beyond.</a> Mol Cancer. 23 (1), 131(2024).</li>
<li>Hsieh, W. C., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Spatial+multi-omics+analyses+of+the+tumor+immune+microenvironment%5BTitle%5D)+AND+%22J+Biomed+Sci%22%5BJournal%5D)">Spatial multi-omics analyses of the tumor immune microenvironment.</a> J Biomed Sci. 29 (1), 96(2022).</li>
<li>Wang, Z., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Gdf15+induces+immunosuppression+via+cd48+on+regulatory+t+cells+in+hepatocellular+carcinoma%5BTitle%5D)+AND+%22J+Immunother+Cancer%22%5BJournal%5D)">Gdf15 induces immunosuppression via cd48 on regulatory t cells in hepatocellular carcinoma.</a> J Immunother Cancer. 9 (9), e002787(2021).</li>
<li>Krams, S. M., Schaffert, S., Lau, A. H., Martinez, O. M. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Applying+mass+cytometry+to+the+analysis+of+lymphoid+populations+in+transplantation%5BTitle%5D)+AND+%22Am+J+Transplant%22%5BJournal%5D)">Applying mass cytometry to the analysis of lymphoid populations in transplantation.</a> Am J Transplant. 17 (8), 1992-1999 (2017).</li>
</ol>

<table><tbody><tr><td>1×PBS</td><td>HyClone</td><td>SH30256.01</td><td></td></tr><tr><td>10×PBS</td><td>HyClone</td><td>SH30256.01</td><td></td></tr><tr><td>100 mm×20 mm tissue-culture-treated culture dish</td><td>Corning</td><td>430167</td><td></td></tr><tr><td>1000 mL pipette tips</td><td>Rainin</td><td>30389218</td><td></td></tr><tr><td>15 mL centrifuge tube</td><td>NEST</td><td>601052</td><td></td></tr><tr><td>200 mL pipette tips</td><td>Rainin</td><td>30389241</td><td></td></tr><tr><td>40 mm nylon cell strainer/70-mm nylon cell strainer</td><td>Falcon</td><td>352340</td><td></td></tr><tr><td>50 mL centrifuge tube</td><td>NEST</td><td>602052</td><td></td></tr><tr><td>70 μm syringe fifilter</td><td>Sangon Biotech</td><td>F613462-9001</td><td></td></tr><tr><td>Anti-Human CCR2 Antibody (clone: K036C2)</td><td>BioLegend</td><td>357224</td><td></td></tr><tr><td>Anti-Human CCR3 Antibody (clone: 5E8)</td><td>BioLegend</td><td>310724</td><td></td></tr><tr><td>Anti-Human CCR7 Antibody (clone: G043H7)</td><td>BioLegend</td><td>353240</td><td></td></tr><tr><td>Anti-Human CD103 Antibody (clone: Ber-ACT8)</td><td>BioLegend</td><td>350202</td><td></td></tr><tr><td>Anti-Human CD115 Antibody (clone: 9-4D2-1E4)</td><td>BioLegend</td><td>347314</td><td></td></tr><tr><td>Anti-Human CD117 Antibody (clone: 104D2)</td><td>BioLegend</td><td>313201</td><td></td></tr><tr><td>Anti-human CD11b Antibody (clone: 1CRF44) </td><td>BD</td><td>562721</td><td></td></tr><tr><td>Anti-human CD11c Antibody (clone: B-ly6) </td><td>BD</td><td>563026</td><td></td></tr><tr><td>Anti-Human CD123 Antibody (clone: 6H6)</td><td>BioLegend</td><td>306002</td><td></td></tr><tr><td>Anti-Human CD127 Antibody (clone: A019D5)</td><td>BioLegend</td><td>351337</td><td></td></tr><tr><td>Anti-Human CD13 Antibody (clone: WM19)</td><td>BioLegend</td><td>301701</td><td></td></tr><tr><td>Anti-Human CD138 Antibody (clone: MI15)</td><td>BioLegend</td><td>356535</td><td></td></tr><tr><td>Anti-human CD14 Antibody (clone: HCD14)</td><td>BioLegend</td><td>325604</td><td></td></tr><tr><td>Anti-Human CD141 Antibody (clone: M80)</td><td>BioLegend</td><td>344102</td><td></td></tr><tr><td>Anti-Human CD15 Antibody (clone: QA19A61)</td><td>BioLegend</td><td>376302</td><td></td></tr><tr><td>Anti-human CD16 Antibody (clone: B7311) </td><td>BD</td><td>561313</td><td></td></tr><tr><td>Anti-Human CD161 Antibody (clone: HP-3G10)</td><td>BioLegend</td><td>339902</td><td></td></tr><tr><td>Anti-Human CD163 Antibody (clone: GHI/61)</td><td>BioLegend</td><td>333603</td><td></td></tr><tr><td>Anti-Human CD169 Antibody (clone: 7-239)</td><td>BioLegend</td><td>346002</td><td></td></tr><tr><td>Anti-human CD19 Antibody (clone: HIB19)</td><td>BioLegend</td><td>302226</td><td></td></tr><tr><td>Anti-Human CD1c Antibody (clone: L161)</td><td>BioLegend</td><td>331501</td><td></td></tr><tr><td>Anti-Human CD20 Antibody (clone: 2H7)</td><td>BioLegend</td><td>302301</td><td></td></tr><tr><td>Anti-Human CD206 Antibody (clone: 15-2)</td><td>BioLegend</td><td>321151</td><td></td></tr><tr><td>Anti-Human CD24 Antibody (clone: ML5)</td><td>BioLegend</td><td>311129</td><td></td></tr><tr><td>Anti-Human CD25 Antibody (clone: BC96)</td><td>BioLegend</td><td>302624</td><td></td></tr><tr><td>Anti-human CD3 Antibody (clone: UCHT1) </td><td>BD</td><td>555916</td><td></td></tr><tr><td>Anti-Human CD31 Antibody (clone: W18200D)</td><td>BioLegend</td><td>375902</td><td></td></tr><tr><td>Anti-Human CD32 Antibody (clone: FUN-2)</td><td>BioLegend</td><td>303232</td><td></td></tr><tr><td>Anti-Human CD326 Antibody (clone: CO17-1A)</td><td>BioLegend</td><td>369812</td><td></td></tr><tr><td>Anti-Human CD33 Antibody (clone: WM53)</td><td>BioLegend</td><td>303402</td><td></td></tr><tr><td>Anti-human CD4 Antibody (clone: L200) </td><td>BD</td><td>563094</td><td></td></tr><tr><td>Anti-Human CD45 Antibody (clone: HI30) </td><td>BD</td><td>563716</td><td></td></tr><tr><td>Anti-Human CD45RO Antibody (clone: UCHL1)</td><td>BioLegend</td><td>304220</td><td></td></tr><tr><td>Anti-human CD56 Antibody (clone: 5.1H11)</td><td>BioLegend</td><td>362510</td><td></td></tr><tr><td>Anti-Human CD64 Antibody (clone: S18012C)</td><td>BioLegend</td><td>399502</td><td></td></tr><tr><td>Anti-Human CD66b Antibody (clone: 6/40c)</td><td>BioLegend</td><td>392917</td><td></td></tr><tr><td>Anti-human CD68 Antibody (clone: Y1/82A)</td><td>BioLegend</td><td>333808</td><td></td></tr><tr><td>Anti-Human CD69 Antibody (clone: FN50)</td><td>BioLegend</td><td>310902</td><td></td></tr><tr><td>Anti-Human CD7 Antibody (clone: 4H9/CD7)</td><td>BioLegend</td><td>395602</td><td></td></tr><tr><td>Anti-human CD8 Antibody (clone: RPA-T8) </td><td>BD</td><td>557750</td><td></td></tr><tr><td>Anti-Human CD80 Antibody (clone: W17149D)</td><td>BioLegend</td><td>375402</td><td></td></tr><tr><td>Anti-Human CD86 Antibody (clone: BU63)</td><td>BioLegend</td><td>374202</td><td></td></tr><tr><td>Anti-Human FOXP3 Antibody (clone: 206D)</td><td>BioLegend</td><td>320101</td><td></td></tr><tr><td>Anti-Human HLA_ABC Antibody (clone: W6/32)</td><td>BioLegend</td><td>311426</td><td></td></tr><tr><td>Anti-human HLA-DR Antibody (clone: L243)</td><td>BioLegend</td><td>307650</td><td></td></tr><tr><td>Anti-Human IgD Antibody (clone: IA6-2)</td><td>BioLegend</td><td>348211</td><td></td></tr><tr><td>Anti-Human Ki67 Antibody (clone: Ki-67)</td><td>BioLegend</td><td>350501</td><td></td></tr><tr><td>Anti-Human PD_L2 Antibody (clone: MH22B2)</td><td>BD</td><td>567783</td><td></td></tr><tr><td>Anti-Human PD1 Antibody (clone: EH12.2H7)</td><td>BioLegend</td><td>329951</td><td></td></tr><tr><td>Anti-Human PDL1 Antibody (clone: MIH2)</td><td>BioLegend</td><td>393602</td><td></td></tr><tr><td>Anti-human TCR-γδ Antibody (clone: B1) </td><td>BD</td><td>740415</td><td></td></tr><tr><td>Cell cryopreservation

analisi della citometria di massa delle risposte immunitarie sistemiche e locali nel carcinoma epatocellulare

Mass Cytometry Analysis of Systemic and Local Immune Responses in Hepatocellular Carcinoma

Analisi della citometria di massa delle risposte immunitarie sistemiche e locali nel carcinoma epatocellulare

Hepatocellular carcinoma (HCC) is one of the most common and deadliest forms of liver cancer worldwide. Despite advances in treatment, the prognosis for ...

mass-cytometry-analysis-systemic-local-immune-responses

Research

Ricerca

JoVE Journal

Biology

Biologia

Qui descriviamo un metodo per separare e arricchire i componenti del microambiente tumorale immuni e non immuni in tumori sottocutanei stabiliti. Questa tecnica permette l'analisi separata di tumore immuni si infiltra in e frazioni non immune tumore che possono consentire la caratterizzazione completa del microambiente tumorale immuni.

Arricchimento e caratterizzazione dei tumore immuni e Non immuni microambienti in tumori murini sottocutanei stabiliti

Qui descriviamo un approccio proteomico di singola cellula per valutare immunitario fenotipica e funzionale (induzione di citochine intracellulari) alterazioni nei campioni di sangue periferico intero, analizzati tramite citometria a massa.

Cella singola analisi di Immunophenotype e produzione di citochine nel sangue periferico intero tramite citometria a massa

Qui, descriviamo lo sviluppo di un modello murino clinicamente rilevante del cancro al fegato che riassume le caratteristiche immunitarie tipiche del cancro epatocellulare (HCC).

Un modello di topo ortotopico oncogenico indotto dall'epatocito del cancro epatocellulare in aumento nell'impostazione dell'infiammazione epatica e della fibrosi

L'evasione dell'eradicazione mediata da cellule naturali (NK) da parte delle cellule tumorali è importante per l'inizio e la progressione del cancro. Qui, presentiamo due protocolli non basati sulla radioattività per valutare la citotossicità mediata dalla cellula NK verso le cellule tumorali epatiche. Inoltre, viene presentato un terzo protocollo per analizzare la migrazione delle celle NK.

Misurazione della citotossicità e della migrazione mediata da cellule Killer naturali nel contesto delle cellule tumorali epatiche

Qui, descriviamo una strategia semplice e accessibile per visualizzare, quantificare e mappare le cellule immunitarie nelle sezioni del tessuto tumorale incorporate con paraffina. Questa metodologia combina le tecniche di imaging e analisi digitale esistenti con lo scopo di espandere la capacità di multiplexing e l'analisi multiparametrica dei saggi di imaging.

Visualizzazione, quantificazione e mappatura delle popolazioni di cellule immunitarie nel microambiente tumorale

Mancano modelli completi in vitro che ricapitolino fedelmente la malattia umana pertinente. Il presente studio presenta la creazione e la coltura tridimensionale (3D) di sferoidi tumorali, uno strumento affidabile in vitro per studiare l'interazione tumore-stromale nel carcinoma epatocellulare umano.

Un modello sferoide tridimensionale per studiare l'interazione tumore-stromale nel carcinoma epatocellulare

Questo protocollo delinea la generazione di topi del sistema immunitario umano (HIS) per studi immuno-oncologici. Le istruzioni e le considerazioni nell'uso di questo modello per testare immunoterapici umani su tumori umani impiantati in questo modello sono presentate con un'enfasi sulla caratterizzazione della risposta del sistema immunitario umano al tumore.

Test di immunoterapie del cancro in un modello murino umanizzato che porta tumori umani

Qui, descriviamo in dettaglio un protocollo semplice, veloce e affidabile di citometria a flusso multiparametrica e tumor-on-a-chip per monitorare e caratterizzare le fasi che costituiscono il ciclo cancro-immunità. In effetti, una comprensione approfondita delle interazioni tra cancro e cellule immunitarie fornisce informazioni critiche per superare in astuzia i tumori e guidare l'assistenza clinica.

Sistemi in vitro di co-coltura per riprodurre il ciclo cancro-immunità

La presenza di mastociti nel margine interno e nelle aree peritumorali del carcinoma epatocellulare dopo la resezione conferisce una prognosi favorevole. Questo studio sostiene che il software di analisi delle immagini QuPath è una piattaforma promettente che potrebbe soddisfare le esigenze di riproducibilità, coerenza e accuratezza nella patologia digitale.

I mastociti nel microambiente del carcinoma epatocellulare conferiscono una prognosi favorevole: uno studio retrospettivo utilizzando il software di analisi delle immagini QuPath 

Questo video dimostra la dissezione e la rimozione del timo del feto e la preparazione delle colture ex vivo di 2-dGuo trattati con timo.

La preparazione di 2-dGuo-trattati Organ Culture Timo

Scopri la citometria di massa per analizzare le risposte immunitarie sistemiche e locali nel carcinoma epatocellulare. Questo metodo identifica 14 tipi cellulari distinti e supporta strategie terapeutiche personalizzate.

Analisi della citometria di massa delle risposte immunitarie sistemiche e locali nel carcinoma epatocellulare

Esplora altri video